0.00 (0.00)
Prev Close 0.01
Open 0.01
Day Low/High 0.01 / 0.01
52 Wk Low/High 0.00 / 0.01
Volume 5.00K
Exchange OTC
Shares Outstanding 156.44B
Market Cap 1.17M
Div & Yield N.A. (N.A)

Medicis Ironing Out Wrinkles

The company lost its bid for Inamed and posted a weak quarter, but its deal for Reloxin's a real coup.

Medicis Turns Loss Into Win

The company buys the rights to an experimental Botox-like drug.

Readers Rise to Inamed, Allergan Challenge

Two readers figured out the options trading around this deal.

Reader Challenge: Inamed and Allergan

We've got 45 minutes to answer three questions about options trading around this deal.

FTC Clears Inamed Deal

Allergan moves a step closer.

Today's Health Winners and Losers

Genomic Health shares get hammered after a downgrade.

Cramer's 'Mad Money' Recap: Heavy Duty

Cramer says the fat-fighting craze offers several good stock plays.

Mentor Pulls Profit Forecast

The company also misses estimates for the third quarter.

Allergan Extends Inamed Offer

The exchange offer was scheduled to expire Tuesday but will now end Feb. 22.

Allergan Gets Past Estimates

Net sales exceeded expectations, coming in at $594.9 million.

Inamed Buy Gets Europe OKs

The deal is still waiting for clearance from the U.S. Federal Trade Commission.

Cramer's 'Mad Money' Recap: Vanity Fare

Cramer says there's money to be made from the boomer generation's quest for artificial youth .

Inamed Goes With Allergan

Medicis withdrew its agreement to buy Inamed and received a $90 million break-up fee.

Medicis Walks Away From Inamed

The company says it will get a $90 million break-up fee.

Inamed Board Takes Swiss Approach

However, the company's directors say Allergan's offer is superior to the proposal from Medicis.

Wide Field Looking to Trim Weight

Medtronic and Nastech are among a host of players aiming to cut obesity rates.

Medicis Takes Firm Line

The company tells Inamed to reject Allergan's offer or prepare to pay up.

Mentor Plots Cosmetic Change

There's a new twist in the tale of Botox and breast implants.

Mentor Offers $2.2 Billion for Medicis

Medicis rejects the offer.

Medicis CEO Keeps His Wits

If Inamed goes with Allergan, he says his firm won't rethink its business strategy.

StreetNotes: A Daily Roundup of Street Research

Who made what calls.

Inamed Says Allergan Bid Is Superior

It directs management to evaluate the offer.

Allergan Bids for Inamed

The company offers $3.2 billion.

Stay Quick If You Go Against This Trend

We're close to a more lasting rally, but be aware of recent technical damage.

Inamed Gains FDA Nod

The company could soon join rival Mentor in selling silicone gel breast implants.

Medtronic Goes for Shock Value

The company hopes a fat-fighting device can give it more heft.

Traders, Look Sharp for a Bounce

The Arms Index numbers still indicate that a short-term rally -- only for the nimble -- is almost upon us.

Mentor's Mum on FDA Progress

But the company says first-quarter earnings beat estimates.

Mentor Gets Conditional Approval for Implant

Neither the agency nor the company would provide details on the conditions imposed by the FDA.

Mentor Lifts Profit Forecast

The company reported fourth-quarter results that exceeded analysts' estimates.